Tropic Biosciences: How a $875M Deep Tech Pioneer Is Reshaping the Industry

A comprehensive analysis of Tropic Biosciences's funding history, investors, competitive position, and growth trajectory in the Deep Tech space.

Jul 19, 2028
AI Funding Team
Share

Executive Summary

Tropic Biosciences is a Deep Tech company founded in null and headquartered in Norwich, United Kingdom. Led by (), the company has raised a total of $196M across 2 funding round(s), reaching a valuation of $875M. UK agricultural biotech company using CRISPR gene editing and proprietary GEiGS technology to develop disease-resistant, climate-resilient tropical crops including bananas, coffee, and rice.

The AI funding landscape continues to evolve rapidly, with significant capital flowing into companies pushing the boundaries of artificial intelligence. This period's activity reflects both growing investor confidence and the increasing maturity of the ecosystem. Deal sizes and valuations continue to climb as AI transitions from experimental technology to core enterprise infrastructure.

Company Overview

Tropic Biosciences is a Norwich-based agricultural biotechnology company applying cutting-edge genetic innovation to tropical agriculture. Using CRISPR gene editing combined with its proprietary GEiGS (Gene Editing induced Gene Silencing) platform, Tropic develops crop varieties with improved disease resistance, reduced pesticide dependency, and enhanced climate resilience. The company focuses on staple tropical crops — bananas, coffee, and rice — that are critical to global food security but increasingly threatened by climate change and disease. Tropic's banana program addresses Panama disease (Tropical Race 4), a devastating fungal pathogen that threatens global banana production. The company's gene-edited varieties aim to provide durable resistance without relying on chemical treatments, enabling brighter futures for tropical growers worldwide.

DetailValue
Foundednull
HeadquartersNorwich, United Kingdom
SectorDeep Tech
SubsectorAgricultural Biotech
EmployeesN/A
Founder()
Websitehttps://tropic.bio

This area of the AI market continues to attract significant investor attention, reflecting the sector's rapid growth and substantial long-term potential.

Funding History

Tropic Biosciences has raised a total of $196M across 2 round(s). Below is a complete breakdown of every known funding round.

RoundAmountValuationDateLead Investor(s)All Investors
Series C$105M$875MMar 13, 2026UndisclosedUndisclosed
Undisclosed$91M$609MMar 13, 2026UndisclosedUndisclosed

Total Capital & Valuation

  • Total Raised: $196M
  • Latest Valuation: $875M (as of Mar 13, 2026)
  • Latest Round: Series C — $105M (Mar 13, 2026)
  • Number of Rounds: 2

The funding trajectory demonstrates accelerating momentum, with round sizes and valuations increasing as key milestones are delivered and market presence expands.

Key Investors

Tropic Biosciences has attracted 1 known investor(s) across its funding rounds. Below is a profile of each.

Undisclosed

> Undisclosed is an investor in AI companies.

The investor composition signals strong institutional backing and strategic interest. The presence of repeat investors alongside new participants suggests growing confidence in execution and market trajectory.

Sector Analysis: Deep Tech

Tropic Biosciences operates in the Deep Tech sector (specifically Agricultural Biotech). Understanding the broader sector landscape provides context for the company's position and growth potential.

Other companies in the Deep Tech sector tracked by AI Funding:

CompanyFoundedLocationTotal RaisedLatest Valuation
TeluranullGermany$4M$33M
Cellbox SolutionsnullBerlin, Germany$19M$75M
IsembardnullSan Francisco, CA$50M$250M
SeprifynullMarly, Switzerland$13M$89M
Lux AeternanullDenver, CO$10M$50M
Xscape PhotonicsnullFort Lee, NJ$37M$247M
Roboze2013Bari, Italy$0N/A
Level NinenullSan Francisco, CA$4M$27M
RubinullSan Francisco, CA$8M$50M
AutosciencenullCalifornia, USA$14M$93M
PADOnullSan Francisco, CA$6M$40M
ArcnullSan Francisco, CA$50M$333M
Arc Boat CompanynullSan Francisco, CA$50M$333M
RegenonullUnited Kingdom$422K$3M
PAVEnullSan Francisco, CA$40M$200M
CellbricksnullSan Francisco, CA$10M$67M
Pave SpacenullEurope$40M$200M
Epoch BiodesignnullLondon, UK$13M$86M
ArinnanullSan Francisco, CA$4M$20M
MountlynullFrench Alps, France$0N/A
EnerVenuenullSan Francisco, CA$300M$2.0B
ALSOnullSan Francisco, CA$200M$1.7B
HermeusnullSan Francisco, CA$350M$2.3B
AltiliumnullUnited Kingdom$19M$123M

Looking ahead, deal activity is expected to remain strong as major AI companies continue scaling operations and new entrants attract institutional capital. Key areas to watch include frontier model development, enterprise AI adoption, and infrastructure plays that underpin the broader ecosystem.

Competitive Landscape

Tropic Biosciences competes with 24 other tracked Deep Tech companyies in our database:

  • Telura: Deep-tech geothermal energy company developing electro-impulse drilling and superhot rock technology to unlock next-generation clean baseload power worldwide.
  • Cellbox Solutions: German biotech logistics company developing precision temperature-controlled transport systems for living cells and biological materials. Their patented packaging technology maintains exact thermal conditions during shipping, enabling hospitals, research labs, and pharmaceutical companies to safely transport cell therapies, tissue samples, and other sensitive biologics across the globe.
  • Isembard: Industrial acceleration company applying AI and advanced engineering to forge new approaches to manufacturing and industrial processes. Isembard focuses on building AI-driven tools and systems that help manufacturers optimize production lines, reduce defects, and accelerate product development cycles, targeting sectors like aerospace, energy, and defense where precision and reliability are paramount.
  • Seprify: Deep-tech materials company developing cellulose-based functional materials as sustainable alternatives to titanium dioxide across cosmetics, food, pharma, and coatings.
  • Lux Aeterna: Space technology company building the world's first reusable satellite fleet for rapid deployment, retrieval, in-orbit servicing, and payload recovery.
  • Xscape Photonics: Xscape Photonics develops silicon photonics solutions using light instead of electricity to move data, addressing bandwidth bottlenecks in AI data centers. As AI training demands exponentially more interconnect bandwidth, Xscape's optical technology is positioned to become essential infrastructure for next-generation AI supercomputers.
  • Roboze: Italian defence-tech and aerospace 3D printing company using AI to optimize additive manufacturing for critical components. Roboze builds super-precision 3D printers capable of producing parts from high-performance polymers and composite materials, serving defense, aerospace, and energy clients who need production-grade components with metal-equivalent strength and heat resistance.
  • Level Nine: Builds a modular "Lego for catalysts" platform intended to simplify catalyst development, assembly and experimentation as presented in its pitch deck.
  • Rubi: Converts captured CO₂ into engineered materials and feedstocks for industrial, commercial, and circular-economy applications via carbon-utilization processes.
  • Autoscience: Builds AI systems intended to automate scientific research workflows and replace human researchers across research‑intensive organizations.
  • PADO: Builds solutions to improve energy efficiency in data centres facing rising power demands from AI and cloud workloads.
  • Arc: Designs and manufactures high-performance electric speed boats and is expanding its product line and sales efforts into defense maritime applications.
  • Arc Boat Company: Designs and manufactures electric boats for competitive racing and consumer marine markets, positioning itself in the accelerating electric-boat industry.
  • Regeno: Develops and prototypes next-generation wind turbines focused on advancing turbine technology and accelerating deployment for sustainable power generation in the renewables sector.
  • PAVE: Builds technology and services to rapidly relocate satellites between Earth orbits, enabling on-demand satellite repositioning and flexible orbital logistics.
  • Cellbricks: Develops 3D tissue implants and organ-replacement technologies to enable regenerative-medicine therapies and reduce reliance on donor organs.
  • Pave Space: Designs and manufactures spacecraft and space systems for commercial and institutional customers, with a focus on serving Europe's expanding space industry.
  • Epoch Biodesign: Develops biological recycling processes and commercial plants to break down and recover nylon 6.6 waste for circular material supply chains.
  • Arinna: Develops compact, high-efficiency power generation and energy-management systems to solve spacecraft and orbital infrastructure power challenges.
  • Mountly: Operates a Deliveroo-style on-demand food and goods delivery service serving residents, tourists and businesses in the French Alps.
  • EnerVenue: Develops and manufactures long-duration, non-lithium rechargeable battery systems and energy storage solutions for grid, industrial, and commercial applications, focusing on scalable manufacturing.
  • ALSO: Designs and manufactures electric vehicles optimized for urban last-mile delivery, operating as a Rivian spinoff that reached unicorn status.
  • Hermeus: Designs and manufactures supersonic fighter jets and associated aerospace systems for military and defense applications.
  • Altilium: Builds and operates the UK's first electric vehicle battery recycling facility to recover materials from end-of-life EV batteries.

At a valuation of $875M, Tropic Biosciences ranks behind EnerVenue, ALSO, Hermeus in sector valuation.

The competitive landscape remains dynamic, with established players and well-funded startups vying for market share. Differentiation increasingly comes from technology depth, go-to-market execution, and strategic partnerships that provide distribution advantages.

Revenue & Growth

Revenue run rate data is not publicly available for Tropic Biosciences at this time.

Revenue growth has been a key driver of investor interest, with strong product-market fit and expanding enterprise customer adoption underpinning the company's valuation trajectory.

Leadership

,

Tropic Biosciences was founded in null by **, who serves as . Under 's leadership, the company has grown to approximately an undisclosed number of employees and raised $196M in total funding.

Under current leadership, the company has navigated rapid growth while maintaining technical excellence and a clear strategic vision for the future of AI.

Frequently Asked Questions

How much funding has Tropic Biosciences raised?

Tropic Biosciences has raised a total of $196M across 2 funding round(s). The most recent round was a Series C of $105M on Mar 13, 2026.

What is Tropic Biosciences's valuation?

As of its most recent funding round (Series C, Mar 13, 2026), Tropic Biosciences is valued at $875M.

Who are Tropic Biosciences's investors?

Tropic Biosciences's investors include Undisclosed. These investors have collectively committed $196M across 2 round(s).

When was Tropic Biosciences founded?

Tropic Biosciences was founded in null by and is headquartered in Norwich, United Kingdom.

What sector does Tropic Biosciences operate in?

Tropic Biosciences operates in the Deep Tech sector, specifically in Agricultural Biotech. Other companies in this sector include Telura, Cellbox Solutions, Isembard, Seprify, Lux Aeterna, Xscape Photonics, Roboze, Level Nine, Rubi, Autoscience, PADO, Arc, Arc Boat Company, Regeno, PAVE, Cellbricks, Pave Space, Epoch Biodesign, Arinna, Mountly, EnerVenue, ALSO, Hermeus, Altilium.

Who is the CEO of Tropic Biosciences?

** is the of Tropic Biosciences.

Get the Weekly AI Funding Roundup

Every AI funding deal, delivered weekly. No spam, unsubscribe anytime.

Related Insights

Explore the Data

Investors mentioned